Endocrine Abstracts

Introduction: Conventional imaging for prostate cancer typically utilizes cross-sectional CT and MRI scanning, along with Tc99 bone scanning for bone metastases. All of these modalities have relatively poor sensitivity and specificity, particularly for men with suspected recurrence following radical prostatectomy or radiotherapy. PSMA PET is rapidly emerging as a superior imaging option.Objective: To give a clinical perspective of the role PSMA PET for s...

Introduction: Lack of clinically relevant experimental models of human prostate cancer hampers evaluation of novel therapeutic agents. Currently, androgen deprivation therapy is the gold standard treatment for advanced prostate cancer, but inevitably cells survive and repopulate the tumour. Castrate-resistant cells are critical therapeutic targets for more effective treatments but current model systems cannot determine when they arise in disease progression and are unable to r...

Ga-68 labelled urea-based inhibitors of the prostate specific membrane antigen (PSMA), such as 68Ga-HBED-PSMA-11, are promising peptides for targeting prostate cancer. The tris(hydroxypyridinone) (THP) ligand rapidly complexes 68Ga3+ at room temperature, at very low concentration and over a wide pH range, making it possible for the direct elution from a 68Ge/68Ga generator into a cold radiopharmaceutical kit in one step wi...